There are no active treatment options for patients with progressive melanoma brain metastases who have failed treatment with immunotherapy and BRAF-/MEK inhibitors. Dr Iris Dirven, medical oncologist at UZ Brussels presented a single center retrospective analysis in patients with refractory melanoma brain metastases treated with regorafenib and BRAF/MEKi. This combination showed promising anti-tumour activity and is currently being evaluated in a prospective, phase 3 study.
With the educational support of:
 |
 |
 |
 |